Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA1-Deficient Cancers
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Abnormal regulation of progression from G1 to S phase of the cell cycle by altered activity of cyclin-dependent kinases (CDKs) is a hallmark of cancer. However, inhibition of CDKs, particularly CDK2, has not shown selective activity against most cancer cells because the kinase seems to be redundant in control of cell cycle progression. Here, we show a novel role in the DNA damage response and application of CDK inhibitors in checkpoint-deficient cells. CDK2−/− mouse fibroblasts and small interfering RNA–mediated or small-molecule–mediated CDK2 inhibition in MCF7 or U2OS cells lead to delayed damage signaling through Chk1, p53, and Rad51. This coincided with reduced DNA repair using the single-cell comet assay and defects observed in both homologous recombination and nonhomologous end-joining in cell-based assays. Furthermore, tumor cells lacking cancer predisposition genes BRCA1 or ATM are 2- to 4-fold more sensitive to CDK inhibitors. These data suggest that inhibitors of CDK2 can be applied to selectively enhance responses of cancer cells to DNA-damaging agents, such as cytotoxic chemotherapy and radiotherapy. Moreover, inhibitors of CDKs may be useful therapeutics in cancers with defects in DNA repair, such as mutations in the familial breast cancer gene BRCA1. (Cancer Res 2006; 66(16): 8219-26)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 2×
“familial breast cancer genes BRCA1 or ATM (23).”
BackgroundA critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M., & Bonner, W. M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00610-2 · Cited by 2,098
Hickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., & Smith, G. C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2727 · Cited by 1,220
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
Sørensen, C. S., Hansen, L. T., Dziegielewski, J., Syljuåsen, R. G., Lundin, C., Bartek, J., & Helleday, T. (2005) · Nature Cell Biology · doi:10.1038/ncb1212 · Cited by 666 · cited 1×
“An absence of Chk1 phosphorylation also leads to a reduction in ionizing radiation–induced Rad51 foci formation ( 34 ), so we hypothesize that CDK2 acts upstream of this kinase in the DNA damage response and potentially in multiple components of the pathway given the large number of CDK targets found in protein comple…”
Background
Cited by
A Hormone–DNA Repair Circuit Governs the Response to Genotoxic Insult
Goodwin, J. F., Schiewer, M. J., Dean, J. L., Schrecengost, R. S., de Leeuw, R., Han, S., Ma, T., Den, R. B., Dicker, A. P., Feng, F. Y., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0108 · Cited by 364
Targeting CDK2 in cancer: challenges and opportunities for therapy
Tadesse, S., Anshabo, A. T., Portman, N., Lim, E., Tilley, W., Caldon, C. E., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.001 · Cited by 333
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 276
Johnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41402 · Cited by 168
Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
Ferrao, P. T., Bukczynska, E. P., Johnstone, R. W., & McArthur, G. A. (2012) · Oncogene · doi:10.1038/onc.2011.358 · Cited by 133
Self-citation
Metadata
- Authors
- Deans, A. J., Khanna, K. K., McNees, C. J., Mercurio, C., Heierhorst, J., & McArthur, G. A.
- Venue
- Cancer Research
- Published
- 2006-08-15
- Volume
- 66
- Issue
- 16
- Pages
- 8219-8226
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2153856808
- Cited by
- 125
- References
- 4
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA1-Deficient Cancers. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-3945
- The paper
- Deans, A. J., Khanna, K. K., McNees, C. J., Mercurio, C., Heierhorst, J., & McArthur, G. A. (2006). Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA1-Deficient Cancers. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-3945
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.